Skip to Content

PARP inhibitor olaparib shows significant improvement in PFS for patients with relapsed platinum-sensitive ovarian cancer

In this MEDtalk Eric Pujade-Lauraine present the key results of the study retreatment with maintenance olaparib in patients with ovarian cancerpreviously treated with a PARP inhibitor.

Eric Pujade-Lauraine

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top